[Asia Economy Reporter Lee Gwan-joo] Helixmith announced on the 8th that it has signed a memorandum of understanding (MOU) for joint research and business cooperation on cell and gene therapy with Ewha Womans University Medical Center.
Under this agreement, both institutions will mutually cooperate across the entire field of cell and gene therapy, including viral vector technology, gene delivery technology, human cell culture technology, GMP production technology, and related preclinical and clinical expertise.
They also plan to promote the joint use of facilities and equipment, mutual exchange of human resources, and technology development.
Yoo Seung-shin, CEO of Helixmith, said, "Through this agreement, we expect to strengthen our competitiveness in the cell and gene therapy business by combining Helixmith's technologies covering viral vectors, genes, and human cells with the latest medical technologies and clinical research expertise possessed by Ewha Womans University Medical Center." He added, "We will continue to expand partnerships with leading domestic and international companies and institutions to leap forward as a global gene therapy company."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
